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We demonstrate that the biological effect of an oligonucleotide is infl uenced by its route of cellular uptake. 
Utilizing a splice-switching antisense oligonucleotide (SSO) and a sensitive reporter assay involving correction 
of RNA splicing, we examined induction of luciferase in cells treated either with various concentrations of an 
unconjugated (“free”) SSO or an SSO conjugated to a bivalent RGD ligand that promotes binding to the αvβ3 
integrin (RGD-SSO). Under conditions of equal accumulation in cells, the RGD-SSO consistently had a greater 
effect on luciferase induction than the unconjugated SSO. We determined that the RGD-SSO and the uncon-
jugated SSO were internalized by distinct endocytotic pathways, suggesting that the route of internalization 
affects the magnitude of the biological response.
Introduction
There is currently great interest in the possible ther-apeutic uses of siRNA oligonucleotides and rekindled 
interest in antisense oligonucleotides for purposes of mod-
ulation of RNA splicing or antagonism of miRNA (Dean 
and Bennett, 2003; Sazani and Kole, 2003; Stein et al., 2005; 
Gewirtz, 2007; Castanotto and Rossi, 2009; Whitehead et al., 
2009). However, these highly polar molecules do not read-
ily cross biological membranes and enter cells; thus a great 
deal of effort has been devoted to improving the intracellu-
lar delivery of oligonucleotides (Song et al., 2005; Abes et al., 
2007; Li and Szoka, 2007; Li et al., 2008; Meyer et al., 2008). 
A signifi cant portion of this effort has simply dealt with 
increasing the total amount of oligonucleotide delivered, 
while other aspects include targeting to specifi c cell types, 
or improving release from endosomal compartments where 
oligonucleotides tend to initially accumulate. However, rel-
atively little attention has been paid to the details of sub-
cellular traffi cking of oligonucleotides and how this might 
impact their biological effectiveness.
As a test system, we utilized αvβ3 integrin-expressing 
melanoma cells that contain a luciferase reporter gene inter-
rupted by an abnormal intron that prevents expression of 
functional luciferase protein (Alam et al., 2008). Upon ade-
quate delivery of an appropriate splice-switching antisense 
oligonucleotide (SSO) to the nucleus, the intron is spliced out 
and luciferase is expressed, thus providing a very sensitive 
positive readout of oligonucleotide delivery and subsequent 
biological effect (Sazani and Kole, 2003; Roberts et al., 2006). 
We compared the effects of an unconjugated or “free” SSO 
(termed 623) with those of a conjugate comprised of oligo-
nucleotide 623 covalently linked to a cyclic RGD peptide 
that binds with high affi nity to the αvβ3 integrin (RGD-623) 
(Alam et al., 2008). We show that the unconjugated SSO and 
the RGD-conjugated SSO differ in their ability to induce 
luciferase even when they are accumulated to equal levels 
in cells. We further demonstrate that the endocytotic uptake 
pathways for the RGD-SSO and the unconjugated SSO are 
substantially different, particularly in terms of their depen-
dence on the actin cytoskeleton and on dynamin. Since the 
RGD-SSO and the unconjugated SSO are equally potent 
when delivered directly to the cytosol, our observations 
suggest that the endocytotic uptake pathway followed by 




We utilized stable transfectants of human A375SM mela-
noma cells (A375SM-Luc705-B cells) containing a fi refl y lucif-
erase gene cassette that includes an abnormal intron. The 
intranuclear presence of a “splice-switching oligonucleotide” 
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treatment, 1% FBS was added to each well. Twenty-four 
hours after oligonucleotide treatment, medium was replaced 
with DMEM containing 1% FBS, and at 24 hours afterward 
cell lysates were collected for determination of fl uorescence 
intensity, luciferase activity, and total protein content. The 
luciferase assay used a kit (Promega, Madison, WI) and 
measurements were performed on a Monolight 2010 instru-
ment (Analytical Luminescence Laboratory, San Diego, CA). 
Total cellular uptake of Tamra-labeled oligonucleotides was 
monitored using a Nanodrop microfl uorimeter (Nanodrop 
Technologies, Wilmington, DE). After treatment with oli-
gonucleotides, the cells were lysed in Reporter Lysis Buffer 
(Promega) and the Tamra fl uorescence (excitation 560 nm 
and emission 583 nm) was quantitated based on a linear 
standard curve of unconjugated Tamra in buffer.
Confocal microscopy
Intracellular distribution of Tamra-labeled oligonucle-
otides in living cells was examined using an Olympus 
Confocal FV300 fl uorescent microscope with 60× oil immer-
sion objective, as previously described (Alam et al., 2008). 
Glass bottom microwell dishes (35 mm) were obtained from 
MatTek (Ashland, MA).
Results and Discussion
We explored the relationship between cell uptake and 
biological effect (luciferase induction in this case), fi rst by 
performing careful measurements of these parameters 
over a wide range of oligonucleotide concentrations, and 
second by use of molecular and chemical inhibitors to 
(termed oligo 623) that targets an intronic splice site results 
in splicing out of the intron and allows expression of wild-
type luciferase mRNA and protein (Alam et al., 2008). Cells 
were maintained in DMEM containing 100 μg/mL hygro-
mycin B and 10% fetal bovine serum (FBS). Cytochalasin D, 
latrunculin A, methyl-β-cyclodextrin, β-cyclodextrin, and 
amiloride were purchased from Sigma (St. Louis, MO). A 
plasmid expressing a dominant negative (DN) version of 
dynamin (K44A) as a chimera with green fl uorescent pro-
tein (GFP) was obtained from Dr. Joann Trejo, University of 
California, San Diego.
Oligonucleotides
Synthesis and chemical characterization of 2′-O-Me-
phosphorothioate splice-switching oligonucleotide 623 
(5′-GTT ATT CTT TAG AAT GGT GC-3′) and its cyclic RGD 
conjugate (RGD-623) were performed as described previ-
ously (Alam et al., 2008). In both cases, the oligonucleotide 
had a N-carboxy-(tetramethyl-rhodamine) (Tamra) fl uoro-
phore incorporated at the 3′ position. Versions of these mate-
rials containing 5 mismatches to the target splice site were 
also produced.
Cell uptake and luciferase assays
A375SM-Luc705-B cells were plated in 12-well plates at 
1.5 × 105 cells per well in DMEM supplemented with 10% 
FBS. The following day, medium was changed to OPTI-
MEM I (Invitrogen, Carlsbad, CA). Cells were treated with 
either free 623 oligonucleotide or RGD-623 conjugate, or 
















































FIG. 1. Diagram of the RGD-conjugated splice-shifting oligonucleotide (RGD-623). The RGD moiety is conjugated at the 5′ 
position, while a Tamra fl uorophore is at the 3′ position. The oligonucleotide is a 2′-O-Me-phosphorothioate.
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15 units (RLU/μg protein) for 623 but 40 units for RGD-623. 
Similar experiments with any of the mismatched versions 
of 623 or RGD-623 did not result in luciferase induction 
(data not shown). It should be noted that the uptake studies 
described here track the accumulation and retention of the 
fl uorophore; thus, it is possible that this measurement might 
not refl ect accumulation of the oligonucleotide itself if the 
labels were to be cleaved. However, it has been our experi-
ence (Alam et al., 2008; Kang et al., 2008) and that of several 
other laboratories (Turner et al., 2005; Bendifallah et al., 2006; 
El-Andaloussi et al., 2006) that fl uorophore labels placed at 
the 3′ position of stable oligonucleotides provide reasonably 
accurate tracking of oligonucleotides in cell culture experi-
ments such as those described here.
Evaluating the uptake pathway
The simple fl uorometric measurement we report above 
provides information on the total amount of fl uorophore-
labeled oligonucleotide associated with the cell, but it is 
silent concerning the subcellular localization of the accu-
mulated material. To address this issue, we turned to con-
focal fl uorescence microscopy, and to use of chemical and 
molecular inhibitors of endocytosis. Cells employ several 
distinct endocytotic pathways including those involving 
clathrin-coated vesicles, caveolae, and various smooth vesi-
cles (Kirkham and Parton, 2005; Mayor and Pagano, 2007).
Simple fl uorescence microscopic observation of cells 
treated with 623-Tamra or RGD-623-Tamara did not reveal 
obvious differences (data not shown). In both cases the fl uo-
rescent oligonucleotide was primarily found in intracellular 
vesicles, similar to previous descriptions of the subcellular 
distribution of oligonucleotides and peptide–oligonucle-
otide conjugates observed by us and by others (Turner et al., 
2005; Alam et al., 2008). Thus, we sought to probe possible 
differences in uptake and traffi cking pathways by use of 
several putatively selective inhibitors of various endocy-
totic pathways (Parpal et al., 2001; Khalil et al., 2006). Prior to 
uptake experiments, we tested various doses of these agents 
for possible toxicity, and chose doses below those that per-
mitted 90% cell survival (data not shown).
A notable difference was observed with regard to the 
effect of inhibitors of the actin cytoskeleton on cellular 
uptake of 623 vs. RGD-623. As seen in Figure 3A, uptake of 
RGD-623 was substantially reduced by treatment with cyto-
chalasin D, whereas this agent had no effect on uptake of 
unconjugated 623. Use of latrunculin A, another actin inhib-
itor with a mechanism of action distinct from cytochalasin D 
(Aplin and Juliano, 1999; Uriarte et al., 2009), provided essen-
tially the same result (Fig. 3B). Thus a substantial portion 
(~50%) of the uptake of RGD-623 was sensitive to disruption 
of actin fi laments, while uptake of 623 was unaffected. While 
most endocytotic pathways involve actin, there have been 
reports of internalization and traffi cking pathways that are 
not strongly actin-dependent (Damm et al., 2005). Similar 
studies were done with several endocytotic inhibitors that 
putatively have selective effects on clathrin-mediated endo-
cytosis, lipid-raft-mediated endocytosis, and macropinocy-
tosis (Parpal et al., 2001; Khalil et al., 2006), and the results 
are summarized in Table 1. To the extent that the agents used 
can be presumed to be selective, these studies suggest that 
clathrin-coated vesicles are not involved in uptake of 623 
or RGD-623, nor in macropinocytosis. However, uptake of 
perturb uptake and subcellular traffi cking processes. Our 
observations indicate that the free oligonucleotide and the 
RGD–oligonucleotide conjugate are taken up via different 
endocytotic pathways leading to differing degrees of biolog-
ical effectiveness.
Relationship between uptake and biological effect
We used SSO 623 or its cyclic RGD conjugate, both labeled 
at the 3′ position with a Tamra fl uorophore (Fig. 1). A375SM-
Luc705-B cells were exposed to a wide range of concentra-
tions of these molecules (0–500 nM); thereafter, the cells 
were harvested and total cellular accumulation of oligo-
nucleotide was monitored by fl uorimetry, while luciferase 
induction was quantitated by luminometry. Results were 
normalized to cell protein content and the effect on lucif-
erase induction was plotted vs. total cell uptake of fl uores-
cent oligonucleotide. As seen in Figure 2, the plot of effect 
vs. uptake for unconjugated 623 was linear; in contrast, the 
plot for RGD-623 was hyperbolic. Further, the magnitude of 
the luciferase effect at a given level of uptake was substan-
tially greater for the RGD-623 compared to unconjugated 
623, especially at lower levels of uptake. For example, at 20 































FIG. 2. Uptake vs. effect. A375SM-Luc705-B cells (150,000/
well) were treated with varying concentrations of 623-Tamra, 
or RGD-623-Tamra at 37°C for 4 hours in OPTI-MEM. At that 
point, 1% serum was added for 24 hours; the medium was 
then changed to 1% FBS/DMEM for another 24 hours. Cells 
were washed, lysed in reporter lysis buffer, freeze-thawed, 
vortexed, and centrifuged (14,000 rpm, 10 minutes); lucifer-
ase activity, protein concentration, and cell uptake of fl uo-
rescent oligonucleotides were measured as described in 
Materials and Methods. Luciferase activity was expressed 
as relative luminescent units (RLU)/μg protein, while cell 
uptake was expressed as relative fl uorescent units (RFU)/μg 
protein. Results are the means of triplicate determinations. 
Graphs were produced with a curve-fi tting program.
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both RGD-623 and 623 seems to involve lipid-raft structures. 
We also examined the effect of some of the inhibitors on the 
induction of luciferase, as summarized in Table 2.
Dynamin is a small GTPase that plays a key role in pinch-
ing off membrane vesicles (Mayor and Pagano, 2007). Most 
endocytotic pathways depend on the action of dynamin, 
but there have been reports of dynamin-independent endo-
cytosis (Sabharanjak et al., 2002; Massol et al., 2004). We 
examined the potential role of dynamin in oligonucleotide 
uptake in this system by transfecting cells with plasmids 
coding for a chimeric protein comprised of a DN form of 
dynamin linked to GFP. We then treated these cells with 
Tamra-labeled RGD-623 or 623 and observed the extent 
and subcellular distribution of the accumulated fl uorescent 
oligonucleotides. As seen in Figure 4A, expression of high 
levels of DN-dynamin/GFP almost completely blocked the 
accumulation of RGD-623 in intracellular vesicles; cells with 
lower levels of expression of the chimeric protein displayed 
a partial inhibition. Interestingly, as seen in Figure 4B, high 
levels of expression of DN-dynamin/GFP failed to inhibit 
accumulation of 623 into intracellular vesicles. This suggests 
that the uptake pathway for unconjugated 623 oligonucleo-
tide is largely independent of dynamin function.
Thus it seems clear that the endocytotic uptake path-
ways for RGD-623 and unconjugated 623 are distinct, with 
RGD-623 traffi cking at least in part via a lipid raft-dependent, 
actin-dependent, dynamin-dependent pathway, while 623 
utilizes a lipid raft-dependent, actin-independent, dynamin-
insensitive pathway. These discrete uptake and traffi cking 
processes may underlie the different pharmacological effec-
tiveness of these 2 molecules when they are accumulated in 
cells at equal total levels. A portion of the uptake of RGD-623 
seems to take place via the same actin-independent pathway 
as 623; presumably, this is some form of nonspecifi c pinocy-
tosis (Mayor and Pagano, 2007).
Testing intrinsic efficacy and the role of the actin-
dependent component of uptake
An alternative possibility is that RGD-623 and 623 have 
some innate difference in effi cacy. To rule this out, we com-
pared the effects of 623 and RGD-623 when administered 
to intact cells (and thus taken up by endocytosis) vs. effects 
when the oligonucleotides were delivered directly to the 



















































FIG. 3. Effects of actin inhibitors. A375SM-Luc705-B cells 
(150,000/well) were preincubated with (A) cytochalasin D 
or (B) latrunculin A at the indicated concentrations for 1 
hour at 37°C in OPTI-MEM containing 1% FBS. At that point, 
623-Tamra (100 nM) or RGD-623-Tamra (100 nM) were added 
to the wells, and the cells were treated for 24 hours. The cells 
were washed with PBS, and lysed with 1× reporter lysis 
buffer (150 μL). The cell extracts were frozen and thawed, 
vortexed, and centrifuged. Relative fl uorescent units (RFUs) 
were measured using a microfl uorimeter. The uptake data 
was normalized on protein concentration. Results represent 
means and standard deviations of triplicate determinations. 
Uptake was considered as 100% where no inhibitor was 
added.








Control None None 100% 100%
Chlorpromazine 2.5 μM Clathrin-mediated endocytosis None None
Methyl-β-cyclodextrin 1.0 mM Lipid-raft-mediated endocytosis 60% ± 2% 55% ± 1%
β-Cyclodextrin 2.5 mM Lipid-raft-mediated endocytosis 58% ± 2% 62% ± 5%
Amiloride 5 μM Macropinocytosis None None
A375SM-Luc705-B cells were treated with the indicated nontoxic concentration of drugs as well as with 100 
nM of RGD-623-Tamra or 623-Tamra. After 20 hours, the cells were washed, lysed, and uptake of fl uorescent 
oligonucleotide per microgram cell protein was determined as described in Materials and Methods. Results 
were normalized on uptake by the control cells as =100%. Statistically signifi cant differences from control were 
observed only for the cyclodextrin-treated samples.
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actin-dependent uptake process makes a substantial contri-
bution to the pharmacological effect of the RGD-623. Thus 
the observed differences in the ability of 623 and RGD-623 
to induce luciferase may be due to their distinct pathways 
of internalization and subcellular traffi cking, with the 
dynamin-dependent, actin-dependent pathway utilized by 
RGD-623 being particularly effective.
Discussion
We have identifi ed an actin-dependent, dynamin-
dependent pathway for uptake of the RGD-623 oligo-
nucleotide conjugate in A375 cells, and an unusual 
actin-independent, dynamin-independent pathway for 
2003; Touyz et al., 2005). As seen in Figure 5A, RGD-623 
and 623 were equally effective in inducing luciferase when 
delivered directly to the cytosol. These observations suggest 
that there is no difference in the intrinsic effi cacy of 623 and 
RGD-623.
We also tested the effect of cytochalasin D on luciferase 
induction when RGD-623 was administered to intact cells or 
delivered via scrape-loading. As seen in Figure 5B, cytocha-
lasin D had no effect on luciferase induction in the scrape-
loaded cells but it signifi cantly reduced luciferase induction 
when the RGD-623 was accumulated by normal endocytotic 
processes. This indicates, fi rst that the concentrations of 
cytochalasin D used are not toxic to the cells’ transcription, 
splicing, and translation machinery, and second that the 








Control None None 100% 100%
Chlorpromazine 2.5 μM Clathrin-mediated endocytosis 89% ± 9% 97% ± 8%
Amiloride 5 μM Macropinocytosis 110% ± 14% 95% ± 5%
A375SM-Luc705-B cells were treated with the indicated nontoxic concentration of drugs as well as 
with 100 nM of RGD-623-Tamra or 623-Tamra. After 20 hours, the medium was changed and the cells 
were placed in culture medium with 1% serum. After an additional 48 hours, the cells were harvested 
and analyzed for luciferase activity and total protein (RLU/μg) as described in Materials and Methods. 
Results were normalized on the control cells as =100%. Cyclodextrins were not included because they 
proved toxic during the lengthier incubations required in these experiments. There were no statistically 
signifi cant differences between the chloropromazine- or amiloride-treated samples and the controls.
A
B
FIG. 4. Effects of dynamin. A375SM-Luc705-B cells (1 million) were transfected at 90% confl uence with 2 μg of DN dynamin-
GFP plasmid using an Amaxa Nucleoporation system. Cells were then cultured in DMEM plus 10% FBS for 24 hours to 
allow protein expression. The cells were then treated with 100 nM of 623-Tamra or 50 nM of RGD-623-Tamra for 4 hours. 
Cells were then trypsinized and seeded in 35-mm glass bottom microwell dishes previously coated with 5 μg/cm2 of fi bro-
nectin for 1 hour at room temperature. Confocal fl uorescent images were obtained as described in Materials and Methods. 
Cells expressing high levels of DN dynamin-GFP are marked by green arrows while untransfected cells are marked by 
orange arrows and cells with weaker dynamin-GFP expression are not marked. (A) RGD-623-Tamra. (B) 623-Tamra. Results 
are typical of multiple microscopic fi elds observed.
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Many recent studies have sought to increase the pharma-
cological effectiveness of antisense and siRNA oligonucle-
otides by increasing their total cellular uptake. While this is 
no doubt valid, our current studies suggest that it may also 
be worthwhile to consider the pathway of uptake. By target-
ing oligonucleotides to specifi c cell-surface receptors, it may 
be possible both to increase cellular uptake and, at least to 
some degree, to steer the path of intracellular traffi cking in 
a benefi cial manner. At this point, little is known about the 
properties of various endosomal compartments in terms of 
releasing oligonucleotides to the cytosol or nucleus; this may 
prove to be an interesting area of investigation.
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the means and standard deviations of 3 determinations and 
are expressed as RLU/μg protein. (B) Cells were treated 
with 100-nM RGD-623-Tamra in the presence or absence of 
2-μM cytochalasin D. In one set of experiments, the intact 
cells were simply incubated with the oligonucleotide and 
inhibitor in DMEM plus 1% FBS. In the other case, the cells 
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